Viral vectors: A look back and ahead on gene transfer technology

New Microbiologica

Volumn 36, Issue 1, 2013, Pages 1-22

  Vannucci, Laura ^a,b   Lai, Michele ^b,c   Chiuppesi, Flavia ^b   Ceccherini Nelli, Luca ^b   Pistello, Mauro ^b  

^a Castelvecchio Pascoli   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Department of Veterinary Medicine   (United Kingdom)

Author keywords

Gene editing; Gene therapy; Gene transfer vector; Genetic disease; Genetic vaccine; Viral vector

Indexed keywords

ANIMAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; PHYSIOLOGY; REVIEW; VIRUS; VIRUS REPLICATION;

ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; VIRUS REPLICATION; VIRUSES;

EID: 84874640802     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. AGARWALLA P.K., AGHI M.K. (2012). Oncolytic herpes simplex virus engineering and preparation. Methods Mol. Biol. 797, 1-19.
2. ALBERTINI A.A., BAQUERO E., FERLIN A., GAUDIN Y. (2012). Molecular and cellular aspects of rhabdovirus entry. Viruses. 4, 117-139.
3. ALLEN J.M., HALBERT C.L., MILLER A.D. (2000). Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. Mol. Ther. 1, 88-95.
4. ALEXANDER J., WARD S., MENDY J., MANAYANI D.J., FARNESS P., AVANZINI J.B., GUENTHER B., GARDUNO F., JOW L., SNARSKY V., ISHIOKA G., DONG X., VANG L., NEWMAN M.J., MAYALL T. (2012). Pre-clinical evaluation of a replication-competent recombinant ade- novirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One. 7, e31177.
5. BARESE C.N., DUNBAR C.E. (2011) Contributions of gene marking to cell and gene therapies. Hum Gene Ther. 22, 659-668.
6. BARRAZA R.A., POESCHLA E.M. (2008). Human gene therapy vectors derived from feline lentiviruses. Vet. Immunol. Immunopathol. 123, 23-31.
7. BARTOSCH B., VITELLI A., GRANIER, C., GOUJON C., DUBUISSON J., PASCALE S. SCARSELLI E., CORTESE R., NICOSIA A., COSSET F.L. (2003). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278, 41624-41630. (Pubitemid 37310418)
8. BLAESE R.M., CULVER K., MILLER A.D., CARTER C.S., FLEISHER T., CLERICI M., SHEARER G., CHANG L., CHIANG Y., TOLSTOSHEV P., GREENBLATT J.J., ROSENBERG S.A., KLEIN H., BERGER M., MULLEN C.A., RAMSEY W.J., MUUL L., MORGAN R.A., ANDERSONW.F. (1995). T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years Science (New York, N.Y.), 270, 475-480.
9. BOS T.J., DE BRUYNE E., HEIRMAN C., VANDERKERKEN K. (2009). In search of the most suitable lentiviral shRNA system. Curr. Gene Ther. 9, 192-211.
10. BRADER P., WONG R.J., HOROWITZ G., GIL Z. (2012). Combination of pet imaging with viral vectors for identification of cancer metastases. Adv. Drug Deliv. Rev. 64, 749-755.
11. BUKRINSKY M.I., HAFFAR O.K. (1999). HIV-1 nuclear import: in search of a leader. Front. Biosci. 4, 772-781.
12. BURNETT J.C., ZAIA J.A., ROSSI J.J. (2012). Creating genetic resistance to HIV Curr. Opin. Immunol. 24, 625-632.
13. BURTON E.A., WECHUCK J.B., WENDELL S.K., GOINS W.F., FIN D.J., G, J.C. (2001). Multiple applications for replication-defective herpes simplex virus vectors. Stem. Cells. 19, 358-377. (Pubitemid 32900079)
14. CAMPAN M., LIONETTI V., AQUARO G.D., FORINI F., MATTEUCCI M., VANNUCCI L., CHIUPPESI F., DI CRISTOFANO C., FAGGIONI M., MAIOLI M., BARILE L., MESSINA E., LOMBARDI M., PUCCI A, PISTELLO M., RECCHIA F.A. (2011). Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5T cardiac MRI in a 2 rat model of myocardial infarction Am. J. Physiol. Heart Circ. Physiol. 300, 2238-2250.
15. CAMPOS S.K., BARRYM.A. (2007). Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7, 189-204. (Pubitemid 46902201)
16. CARROLL D. (2011). Genome engineering with zinc-finger nucleases. Genetics. 188, 773-782.
17. CASTRO M., XIONG W., PUNTEL M., FARROKHI C., KROEGER K.M., PECHNICK R.N., NG P., LOWENSTEIN P., GHULAM MUHAMMAD A., SALEM A., LACAYO L., KELSON KR., PALMER D.J., LIU C., APPELHANS A. (2012). Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase I clinical trial. Hum. Gene Ther. Methods. Oct 17. [Epub ahead of print].
18. CAVAZZANA-CALVO M., HACEIN-BEY S., DE SAINT BASILE G., GROSS F., YVON E., NUSBAUM P., SELZ F., HUE C., CERTAIN S., CASANOVA J.L., BOUSSO P., DEIST F.L., FISCHER A. (2000). Gene therapy of human severe combined immunodeficienty (SCID)-X1 disease. Science. 288, 669-672. (Pubitemid 30241569)
19. CERESETO A., GIACCA M. (2004). Integration site selection by retroviruses. AIDS Rev. 6, 13-21. (Pubitemid 38607537)
20. CHIUPPESI F., VANNUCCI L., DE LUCA A., LAI M., MATTEOLI B., FREER G., MANSERVIGI R., CECCHERINI-NELLI L., MAGGI F., BENDINELLI M., PISTELLO M. (2012). A lentiviral vector-based, herpes simplex virus type-1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J. Virol. 86, 6563-6574.
21. CIUFFI A. (2008). Mechanisms governing lentivirus integration site selection. Curr. Gene Ther. 8, 419-429.
22. CLÉMENT N., KNOP D.R., BYRNE B.J. (2009). Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum. Gene Ther. 20, 796-806.
23. COURA RDOS S., NARDI N.B. (2010). The state of the art of adeno-associated virus-based vectors in gene therapy. Virol. J. 7, 12.
24. CURRAN M.A., KAISER S.M., ACHACOSO P.L., NOLAN G.P. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1, 31-38.
25. DE SILVA S., BOWERSW.J. (2009). Herpes virus amplicon vectors. Viruses. 1, 594-629.
26. D'APOLITO D., BAIAMONTE E., BAGLIESI M., DIMARZO R., CALZOLARI R., FERRO L., FRANCO V., SPINELLI G., MAGGIO A., ACUTO S. (2009). The sea urchin sns5 insulator protects retroviral vectors from chromosomal position effects by maintaining active chromatin structure. Mol. Ther. 17, 1434-1441.
27. DAVISON A.J., BENKO M., HARRACH B. (2003). Genetic content and evolution of adenoviruses. J. Gen. Virol. 84, 2895-2908. (Pubitemid 37336773)
28. DI NUNZIO F., FÉLIX T., ARHEL N.J., NISOLE S., CHARNEAU P., BEIGNON A.S. (2012). HIV-derived vectors for therapy and vaccination against HIV. Vaccine. 30, 2499-2509.
29. DORER D.E., NETTELBECK D.M. (2009). Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 2, 554-571.
30. DROPULI B. (2011). Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum. Gene Ther. 22, 649-657.
31. DULL T., ZUFFEREY R., KELLY M., MANDEL R.J., NGUYEN M., TRONO D., NALDINI L. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471. (Pubitemid 28471781)
32. EDELSTEIN M.L., ABEDI M.R., WIXON J. (2007). Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 9, 833-842. (Pubitemid 47543250)
33. ELLIS J. (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 16, 1241-1246. (Pubitemid 41611651)
34. ENGELMAN A. (2003). The roles of cellular factors in retroviral integration. Curr. Top. Microbiol. Immunol. 281, 209-238. (Pubitemid 36950687)
35. ERLWEIN O., MCCLURE M.O. (2010). Progress and prospects: foamy virus vectors enter a new age. Gene Ther. 17, 1423-1429.
36. FRECHA C., COSTA C., NÈGRE D., GAUTHIER E., RUSSELL S.J., COSSET F.L. VERHOEYEN E. (2008a). Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood. 112, 4843-4852.
37. FRECHA C., SZÉCSI J., COSSET F.L., VERHOEYEN E. (2008b). Strategies for targeting lentiviral vectors. Curr. Gene Ther. 8, 449-460.
38. FREED E.O. (2001). HIV-1 replication. Somat. Cell Mol. Genet. 26, 13-33. (Pubitemid 35332977)
39. FRIEDMAN G.K., PRESSEY J.G., REDDY A.T., MARKERT J.M., GILLESPIE G.Y. (2009) Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol. Ther. 17, 1125-1135.
40. FUJIWARA T., SHIRAKAWA Y., KAGAWA S. (2011). Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. Expert Rev. Anticancer. Ther. 11, 525-532.
41. FUNKE S., MAISNER A., MÜHLEBACH M.D., KOEHL U., GREZ M., CATTANEO R., CICHUTEK K., BUCHHOLZ C.J. (2008). Targeted cell entry of lentiviral vectors. Mol. Ther. 16, 1427-1436.
42. GAUDET D., MÉTHOT J., DÉRY S., BRISSON D., ESSIEMBRE C., TREMBLAY G., TREMBLAY K., DEWAL J., TWISK J., VAN DEN BULK N., SIER-FERREIRA V., VAN DEVENTER S. (2012). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 10.1038/gt.2012.43.
43. GIACCA S., ZACCHIGNA S. (2012). Virus-mediated gene delivery for human gene therapy. J. Control Release. 161, 377-388.
44. GLAUSER D.L., ACKERMANN M., SAYDAM O. FRAEFEL C. (2006). Chimeric herpes simplex virus/adeno-associated virus amplicon vectors, Curr. Gene Ther. 6, 315-324. (Pubitemid 43905448)
45. GOINS W.F., COHEN J.B., GLORIOSO J.C. (2012). Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol. Dis. 48, 255-270.
46. GÓMEZ C.E., NÁJERA J.L., KRUPA M., PERDIGUERO B., ESTEBAN M. (2011). MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 11, 189-217.
47. GRAHAM F.L., PREVEC L. (1995). Methods for construction of adenovirus vectors. Mol. Biotechnol. 3, 207-220.
48. GRANT K.G., KRISKY D.M., ATAAI M.M., GLORIOSO J.C. (2009). Engineering cell lines for production of replication defective HSV-1 gene therapy vectors. Biotechnol. Bioeng. 102, 1087-1097.
49. GRIEGER J.C., SAMULSKI R.J. (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 507, 229-254.
50. HACEIN-BEY-ABINA S., GARRIGUE A., WANG G.P., SOULIER J., LIM A., MORILLON E., CLAPPIER E., CACCAVELLI L., DELABESSE E., BELDJORD K., ASNAFI V., MACINTYRE E., DAL CORTIVO L., RADFORD I., BROUSSE N., SIGAUX F., MOSHOUS D., HAUER J., BORKHARDT A., BELOHRADSKY B.H., WINTERGERST U., VELEZ M.C., LEIVA L., SORENSEN R., WULFFRAAT N., BLANCHE S., BUSHMAN F.D., FISCHER A., CAVAZZANA-CALVO M. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
51. HACEIN-BEY-ABINA S., HAUER J., LIM A., PICARD C., WANG G.P., BERRY C.C., MARTINACHE C., RIEUX-LAUCAT F., LATOUR S., BELOHRADSKY B.H., LEIVA L., SORENSEN R., DEBRÉ M., CASANOVA J.L., BLANCHE S., DURANDY A., BUSHMAN F.D., FISCHER A., CAVAZZANA-CALVO M. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
52. HACEIN-BEY-ABINA S., VON KALLE C., SCHMIDT M., MCCORMACK M.P., WULFFRAAT N., LEBOULCH P., LIM A., OSBORNE C.S., PAWLIUK R., MORILLON E., SORENSEN R., FORSTER A., FRASER P., ET AL. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302, 415-419. (Pubitemid 37296260)
53. HELLEBRAND E., MAUTNER J., REISBACH G., NIMMERJAHN F., HALLEK M., MOCIKAT R., HAMMERSCHMIDT W. (2006). Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther. 13, 150-162. (Pubitemid 43039907)
54. HOLLON T. (2000). Gene therapy - a loss of innocence. Nat. Med. 6, 1-2.
55. HOLT N., WANG J., KIM K., FRIEDMAN G., WANG X., TAUPIN V., CROOKS G.M., KOHN D.B., GREGORY P.D., HOLMES M.C., CANNON P.M. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV- 1 in vivo. Nat. Biotechnol. 28, 839-847.
56. HOWARTH J.L., YOUN BOK LEE Y., UNEY J.B. (2010). Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting. Cell. Biol. Toxicol. 6, 1-20.
57. HOWE S.J., MANSOUR M.R., SCHWARZWAELDER K., BARTHOLOMAE C., HUBANK M., KEMPSKI H., BRUGMAN M.H., PIKE-OVERZET K., CHATTERS S.J., DE RIDDER D., GILMOUR K.C., ADAMS S., THORNHILL S.I., PARSLEY K.L., STAAL F.J., GALE R.E., LINCH D.C., BAYFORD J., BROWN L., QUAYE M., KINNON C., ANCLIFF P., WEBB D.K., SCHMIDT M., VON KALLE C., GASPAR H.B., THRASHER A.J. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCIDX1 patients. J. Clin. Invest. 118, 3143-3150.
58. JAMES D., ZHAN Q., KLOSS C., ZANINOVIC N., ROSENWAKS Z., RAFII S. (2011). Lentiviral transduction and clonal selection of hESCs with endothelial-specific transgenic reporters. Curr. Protoc. Stem. Cell. Biol. 1, Unit1 F.12.
59. JURGENS C.K., YOUNG K.R., MADDEN V.J., JOHNSON P.R., JOHNSTON R.E. (2012). A novel self-replicating chimeric lentivirus-like particle. J. Virol. 86, 246- 261.
60. KANWAR J.R., KAMALAPURAM S.K., KANWAR R.K. (2011). Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today. 16, 485-494.
61. KAY M.A., GLORIOSO J.C., NALDINI L. (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40. (Pubitemid 32095639)
62. KAUFMANN J.K., NETTELBECK D.M. (2012). Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol. Med. 18, 365-376.
63. KENYON J.C., LEVER A.M. (2011). The molecular biology of feline immunodeficiency virus (FIV). Viruses. 3, 2192-2213.
64. KIEM H.P., JEROME K.R., DEEKS S.G., MCCUNE J.M. (2012). Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell. 10, 137-147.
65. KIM J.W., GULLEY J.L. (2012). Poxviral vectors for cancer immunotherapy. Expert Opin. Biol. Ther. 12, 463-478.
66. KOBINGER G.P., WEINER D.J., YU Q.C. WILSON J.M. (2001). Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19, 225-230. (Pubitemid 32220562)
67. KUBO S., KATAOKA M., TATENO C., YOSHIZATO K., KAWASAKI Y., KIMURA T., FAURE-KUMAR E., PALMER D.J., NG P., OKAMURA H., KASAHARA N. (2010). In vivo stable transduction of humanized liver tissue in chimeric mice via high-capacity adenovirus-lentivirus hybrid vector. Hum. Gene Ther. 21, 40-50.
68. KURTH E.G., PEREMYSLOV V.V., PROKHNEVSKY A.I., KASSCHAU K.D., MILLER M., CARRINGTON J.C., DOLJA V.V. (2012). Virus-derived gene expression and RNA interference vector for grapevine. J. Virol. 86, 6002- 6009.
69. LEDERMAN M.M., ALTER G., DASKALAKIS D.C., RODRIGUEZ B., SIEG S.F., HARDY G., CHO M., ANTHONY D., HARDING C., WEINBERG A., SILVERMAN R.H., DOUEK D.C., MARGOLIS L., GOLDSTEIN D.B., CARRINGTON M., GOEDERT J.J. (2010). Determinants of protection among HIV exposed seronegative persons: an overview. J. Infect. Dis. 202, (Suppl 3): S333-338.
70. LEDFORD H. (2011). Targeted gene editing enters clinic. Nature. 471, 16.
71. LENTZ T.B., GRAY S.J., SAMULSKI R.J. (2012). Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis. 48, 179-1888
72. LEONARD W.J. CYTOKINES AND IMMUNODEFICIENCY DISEASES. (2001). Nat. Rev. Immunol. 1, 200-208.
73. LEWINSKI M.K., BUSHMAN F.D. (2005). Retroviral DNA integration-mechanism and consequences. Adv. Genet. 55, 147-181. (Pubitemid 43580695)
74. LINDEMANN D., RETHWILM A. (2011). Foamy virus biology and its application for vector development. Viruses. 3, 561-585.
75. LUO Y., KOFOD-OLSEN E., CHRISTENSEN R., SØRENSEN C.B., BOLUND L. (2012) Targeted genome editing by recombinant adeno-associated virus (rAAV) vectors for generating genetically modified pigs. J. Genet. Genomics. 39, 269-274.
76. MAC GABHANN F., ANNEX B.H., POPEL A.S. (2010). Gene therapy from the perspective of systems biology. Curr. Opin. Mol. Ther. 12, 570-577.
77. MANIC G., MAURIN-MARLIN A., GALLUZZI L., SUBRA F., MOUSCADET J.F., BURY-MONÉ S. (2012). 3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors. Hum. Gene Ther. Methods 23, 84-97.
78. MANSERVIGI R., ARGNANI R., MARCONI P. (2010). HSV Recombinant Vectors for Gene Therapy. Open Virol. J. 18, 123-1566
79. MARCONI P., ARGNANI R., EPSTEIN A.L., MANSERVIGI R. (2009). HSV as a vector in vaccine development and gene therapy. Adv. Exp. Med. Biol. 655, 118- 144.
80. MARCONI P., MANSERVIGI R., EPSTEIN A.L. (2010). HSV- 1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr. Opin. Drug Discov. Devel. 13, 169-183.
81. MÁTRAI J., CHUAH M.K., VANDENDRIESSCHE T. (2010). Recent advances in lentiviral vector development and applications. Mol. Ther. 18, 477-490.
82. MAURICE M., VERHOEYEN E., SALMON P., TRONO D., RUSSELL S.J. COSSET F.L. (2002). Efficient gene transfer into human primary blood lymphocytes by surface engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 99, 2342-2350. (Pubitemid 34525419)
83. MAZARAKIS N.D., AZZOUZ M., ROHLL J.B., ELLARD F.M., WILKES F.J., OLSEN A.L. CARTER E.E., BARBER R.D., BABAN D.F., KINGSMAN S.M., KINGSMAN A.J., O'MALLEY K., MITROPHANOUS K.A. (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109-2121. (Pubitemid 32998823)
84. MILLER J.C., HOLMES M.C., WANG J., GUSCHIN D.Y., LEE Y.L., RUPNIEWSKI I., BEAUSEJOUR C.M., WAITE A.J., WANG N.S., KIM K.A., GREGORY P.D., PABO C.O., REBAR E.J. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25, 778-785. (Pubitemid 47052191)
85. NALDINI L., BLOMER U., GALLAY P., ORY D., MULLIGAN R., GAGE F.H., VERMA I.M., TRONO D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272, 263- 267. (Pubitemid 26119138)
86. NEGRI D.R., MICHELINI Z., BONA R., BLASI M., FILATI P., LEONE P., ROSSI A., FRANCO M., CARA A. (2011). Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin. Biol. Ther. 11, 739-750.
87. OSTEN P., GRINEVICH V., CETIN A. (2007). Viral vectors: a wide range of choices and high levels of service. Handb. Exp. Pharmacol. 178, 177-202.
88. PAN Y., XIAO L., LI A.S., ZHANG X., SIROIS P., ZHANG J., LJ K. (2012). Biological and biomedical applications of engineered nucleases. Mol. Biotechnol. [Epub ahead of print]).
89. PANTALEO G., ESTEBAN M., JACOBS B., TARTAGLIA J. (2010). Poxvirus vector-based HIV vaccines. Curr. Opin. HIV AIDS. 5, 391-396.
90. PISTELLO M., BONCI F., ZABOGLI E., CONTI F., FREER G., MAGGI F., STEVENSON M., BENDINELLI M. (2010). Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J. Virol. 84, 3845-3856.
91. PISTELLO M., VANNUCCI L., RAVANI A., BONCI F., CHIUPPESI F., DEL SANTO B., FREER G., BENDINELLI M. (2007). Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet. Vaccines Ther. 5, 8.
92. Pistello M. (2012). Cap. 67, page B-370 in Principi di microbiologia medica. Antonelli G, Clementi M., Pozzi G., Rossolini G.M., eds. Casa Editrice Ambrosiana, Milano.
93. POESCHLA E.M., WONG-STAAL F., LOONEY D.J. (1998). Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354-357. (Pubitemid 28144098)
94. PULKKANEN K.J., YLA-HERTTUALA S. (2005). Gene therapy for malignant glioma: current clinical status. Mol. Ther. 12, 585-598. (Pubitemid 41350140)
95. RAPER S.E., CHIRMULE N., LEE F.S., WIVEL N.A., BAGG A., GAO G.P., WILSON J.M., BATSHAW M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158. (Pubitemid 37272241)
96. ROIZMAN B., KNIPE D., WHITLEY R. (2007). Herpes simplex viruses, p. 2501-2602. In: H.P. Knipe DM, ed. Fields Virology, 5th ed ed. Lippincott Williams & Wilkins, Philadelphia.
97. ROLLIER C.S., REYES-SANDOVAL A., COTTINGHAM M.G., EWER K., HILL A.V. (2011). Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23, 377-382.
98. SAENZ D.T., BARRAZA R., LOEWEN N., TEO W., POESCHLA E.M. (2012). Feline immunodeficiency virus-based lentiviral vectors. Cold Spring Harb. Protoc. 2012, 71-76.
99. SAKUMA T., BARRY M.A., IKEDA Y. (2012). Lentiviral vectors: basic to translational. Biochem. J. 443, 603-618.
100. SANDRIN V., BOSON B., SALMON P., GAY W., NÈGRE D., LE GRAND R. TRONO D., COSSET F.L. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and efficiency of transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood. 100, 823-832. (Pubitemid 34832607)
101. SAUKKONEN K., HEMMINKI A. (2004). Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4, 683-696. (Pubitemid 38667814)
102. SHAYAKHMETOV D.M., DI PAOLO N.C., MOSSMAN K.L. (2010). Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol. Ther. 18, 1422-1429.
103. SMITH R.H. (2008). Adeno-associated virus integration: virus versus vector. Gene Ther. 15, 817-822. (Pubitemid 351712614)
104. STAUNSTRUP N.H., MIKKELSEN J.G. (2011). Integrase-defective lentiviral vectors-a stage for nonviral integration machineries. Curr. Gene Ther. 11, 350-362.
105. STEIN L.D. (2004). Human genome: end of the beginning. Nature. 431, 915-916.
106. SUN M., KONG L., WANG X., LU X.G., GAO Q., GELLER A.I. (2005). Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res. 1052, 119-129. (Pubitemid 41116769)
107. SUZUKI Y., CRAIGIE R. (2007). The road to chromatin - nuclear entry of retroviruses. Nat. Rev. Microbiol. 5, 187-196. (Pubitemid 46291278)
108. TRAINER A.H., LEWIS C.R., TUCKER K., MEISER B., FRIEDLANDER M., WARD R.L. (2010). The role of BRCA mutation testing in determining breast cancer therapy. Nat. Rev. Clin. Oncol. 7, 708-717.
109. TRIPATHY M.K., ABBAS W., HERBEIN G. (2011). Epigenetic regulation of HIV-1 transcription. Epigenomics. 3, 487-502.
110. URBAN J.H., MERTEN C.A. (2011). Retroviral display in gene therapy, protein engineering, and vaccine development. ACS Chem. Biol. 6, 61-74.
111. VACCARI M., POONAM P., FRANCHINI G. (2010). Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines. 9, 997- 1005.
112. VALORI C.F., NING K., WYLES M., AZZOUZ M. (2008). Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr. Gene Ther. 8, 406-418.
113. VANNUCCI L., CHIUPPESI F., BEVILACQUA G. AND PISTELLO M. (2010). Exploiting FIV as a tool for preventative strategies against human breast cancer. Vet. Immunol. Immunopathol. 134, 48-53.
114. VERHOEYEN E., DARDALHON V., DUCREY-RUNDQUIST O., TRONO D., TAYLOR N., COSSET F.L. (2003). IL-7 surface- engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 101, 2167-2174. (Pubitemid 36302054)
115. VON MESSLING V., CATTANEO R. (2004). Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 283, 281-312. (Pubitemid 38667563)
116. YAMASHITA M., EMERMAN M. (2006). Retroviral infection of non-dividing cells: old and new perspectives. Virology. 344, 88-93. (Pubitemid 41814454)
117. YANG L., BAILEY L., BALTIMORE D., WANG P. (2006). Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. USA. 103, 11479-11484. (Pubitemid 44182477)
118. YAO Y., NASHUN B., ZHOU T., QIN L., QIN L., ZHAO S., XU J., ESTEBAN M.A., CHEN X. (2012). Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum. Gene Ther. 23, 238-242.
119. YI Y., HAHM S.H., LEE K.H. (2005) Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther. 5, 25-35. (Pubitemid 40246740)
120. WALSH S.R., DOLIN R. (2011). Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev. Vaccines. 10, 1221- 1240.
121. WANG L., QI X., SHEN R., SUN Y., TUVESON D.A. (2009) An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. J Cell Physiol. 219, 365-371.
122. WANG X., SU C., CAO H., LI K., CHEN J., JIANG L., ZHANG Q., WU X., JIA X., LIU Y., WANG W., LIU X., WU M., QIAN Q. (2008). A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 7, 1598-1603.
123. WATSON D.J., KOBINGER G.P., PASSINI M.A., WILSON J.M. WOLFE, J.H. (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 5, 528-537. (Pubitemid 34546082)
124. WEI C.J., BOYINGTON J.C., MCTAMNEY P.M., KONG W.P., PEARCE M.B., XU L., ANDERSEN H., RAO S., TUMPEY T.M., YANG Z.Y., NABEL G.J. (2010). Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 329, 1060-1064.
125. WILEN C.B., TILTON J.C., DOMS R.W. (2012). Molecular mechanisms of HIV entry. Adv. Exp. Med. Biol. 726, 223-242.
126. WOLFE D., MATA M., FINK D.J. (2009). A human trial of HSV-mediated gene transfer for the treatment of chronic painHSV-mediated gene transfer. Gene Ther. 16, 455-460.
127. WONG L.F., AZZOUZ M., WALMSLEY L.E., ASKHAM Z., WILKES F.J., MITROPHANOUS K.A., KINGSMAN S.M., MAZARAKIS N.D. (2004). Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9, 101-111. (Pubitemid 38208333)
128. WONG J., LEE C., ZHANG K., RENNIE P.S., JIA W. (2012). Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr. Pharm. Biotechnol. 13, 1786- 1794.
129. WU X., BURGESS S.M. (2004). Integration target site selection for retroviruses and transposable elements. Cell. Mol. Life Sci. 61, 2588-2596. (Pubitemid 39586519)
130. ZIEGLER L., YANG L., JOO K., YANG H., BALTIMORE D., WANG P. (2008). Targeting lentiviral vectors to antigen- specific immunoglobulins. Hum. Gene Ther. 19, 861-872.
131. ZUFFEREY R., DONELLO J.E., TRONO D., HOPE T.J. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. 74, 2886-2892.